Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway

Documenti analoghi

• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2025)
• Psychosine Alleviates Colitis via Inhibiting Th1 and Th17 Cell Immune Responses in Inflammatory Bowel Diseases
  di: Ritian Lin, et al.
  Pubblicazione: (2025)
• Comments on “Immune Checkpoint Inhibitor‐Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and meta‐Analysis”
  di: Zheng Zhang, et al.
  Pubblicazione: (2026)
• Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease
  di: Choon Jin Ooi, et al.
  Pubblicazione: (2026)
• Iron and Inflammatory Cytokines Synergistically Induce Colonic Epithelial Cell Ferroptosis in Colitis
  di: Mo Wang, et al.
  Pubblicazione: (2024)